A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer
10.1186/s12885-018-4234-8
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2020
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/175397 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
id |
sg-nus-scholar.10635-175397 |
---|---|
record_format |
dspace |
spelling |
sg-nus-scholar.10635-1753972024-04-25T02:38:39Z A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer Sundar, R Rha, S.Y Yamaue, H Katsuda, M Kono, K Kim, H.S Kim, C Mimura, K Kua, L.-F Yong, W.P LIFE SCIENCES INSTITUTE SURGERY DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) CANCER SCIENCE INSTITUTE OF SINGAPORE alkaline phosphatase aspartate aminotransferase cancer vaccine HLA A antigen otgsc a24 otsgc a24 peptide vaccine unclassified drug biological marker cancer vaccine HLA A24 antigen subunit vaccine abdominal pain adult advanced cancer adverse outcome aged alkaline phosphatase blood level anemia antineoplastic activity Article aspartate aminotransferase blood level cancer pain clinical article cohort analysis constipation controlled study coughing cytotoxic T lymphocyte decreased appetite diarrhea dizziness drug effect drug efficacy drug response drug safety drug tolerability dyspepsia dysphagia dyspnea enzyme linked immunospot assay ex vivo study female fever gastrointestinal reflux haplotype human hyperbilirubinemia hyperkalemia hypokalemia hyponatremia immune response injection site erythema injection site ulcer loss of appetite lung infection malaise male myalgia nausea open study overall survival peripheral edema phase 1 clinical trial progression free survival pruritus stomach cancer stomach tumor survival rate treatment outcome upper respiratory tract infection vaccination vomiting cancer staging clinical trial cytotoxicity genetics immunology metabolism metastasis middle aged mortality multimodality cancer therapy pathology stomach tumor Adult Aged Biomarkers Cancer Vaccines Combined Modality Therapy Cytotoxicity, Immunologic Female Haplotypes HLA-A24 Antigen Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Stomach Neoplasms T-Lymphocytes, Cytotoxic Vaccines, Subunit 10.1186/s12885-018-4234-8 BMC Cancer 18 1 332 2020-09-09T10:30:08Z 2020-09-09T10:30:08Z 2018 Article Sundar, R, Rha, S.Y, Yamaue, H, Katsuda, M, Kono, K, Kim, H.S, Kim, C, Mimura, K, Kua, L.-F, Yong, W.P (2018). A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 18 (1) : 332. ScholarBank@NUS Repository. https://doi.org/10.1186/s12885-018-4234-8 1471-2407 https://scholarbank.nus.edu.sg/handle/10635/175397 Unpaywall 20200831 |
institution |
National University of Singapore |
building |
NUS Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NUS Library |
collection |
ScholarBank@NUS |
topic |
alkaline phosphatase aspartate aminotransferase cancer vaccine HLA A antigen otgsc a24 otsgc a24 peptide vaccine unclassified drug biological marker cancer vaccine HLA A24 antigen subunit vaccine abdominal pain adult advanced cancer adverse outcome aged alkaline phosphatase blood level anemia antineoplastic activity Article aspartate aminotransferase blood level cancer pain clinical article cohort analysis constipation controlled study coughing cytotoxic T lymphocyte decreased appetite diarrhea dizziness drug effect drug efficacy drug response drug safety drug tolerability dyspepsia dysphagia dyspnea enzyme linked immunospot assay ex vivo study female fever gastrointestinal reflux haplotype human hyperbilirubinemia hyperkalemia hypokalemia hyponatremia immune response injection site erythema injection site ulcer loss of appetite lung infection malaise male myalgia nausea open study overall survival peripheral edema phase 1 clinical trial progression free survival pruritus stomach cancer stomach tumor survival rate treatment outcome upper respiratory tract infection vaccination vomiting cancer staging clinical trial cytotoxicity genetics immunology metabolism metastasis middle aged mortality multimodality cancer therapy pathology stomach tumor Adult Aged Biomarkers Cancer Vaccines Combined Modality Therapy Cytotoxicity, Immunologic Female Haplotypes HLA-A24 Antigen Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Stomach Neoplasms T-Lymphocytes, Cytotoxic Vaccines, Subunit |
spellingShingle |
alkaline phosphatase aspartate aminotransferase cancer vaccine HLA A antigen otgsc a24 otsgc a24 peptide vaccine unclassified drug biological marker cancer vaccine HLA A24 antigen subunit vaccine abdominal pain adult advanced cancer adverse outcome aged alkaline phosphatase blood level anemia antineoplastic activity Article aspartate aminotransferase blood level cancer pain clinical article cohort analysis constipation controlled study coughing cytotoxic T lymphocyte decreased appetite diarrhea dizziness drug effect drug efficacy drug response drug safety drug tolerability dyspepsia dysphagia dyspnea enzyme linked immunospot assay ex vivo study female fever gastrointestinal reflux haplotype human hyperbilirubinemia hyperkalemia hypokalemia hyponatremia immune response injection site erythema injection site ulcer loss of appetite lung infection malaise male myalgia nausea open study overall survival peripheral edema phase 1 clinical trial progression free survival pruritus stomach cancer stomach tumor survival rate treatment outcome upper respiratory tract infection vaccination vomiting cancer staging clinical trial cytotoxicity genetics immunology metabolism metastasis middle aged mortality multimodality cancer therapy pathology stomach tumor Adult Aged Biomarkers Cancer Vaccines Combined Modality Therapy Cytotoxicity, Immunologic Female Haplotypes HLA-A24 Antigen Humans Male Middle Aged Neoplasm Metastasis Neoplasm Staging Stomach Neoplasms T-Lymphocytes, Cytotoxic Vaccines, Subunit Sundar, R Rha, S.Y Yamaue, H Katsuda, M Kono, K Kim, H.S Kim, C Mimura, K Kua, L.-F Yong, W.P A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
description |
10.1186/s12885-018-4234-8 |
author2 |
LIFE SCIENCES INSTITUTE |
author_facet |
LIFE SCIENCES INSTITUTE Sundar, R Rha, S.Y Yamaue, H Katsuda, M Kono, K Kim, H.S Kim, C Mimura, K Kua, L.-F Yong, W.P |
format |
Article |
author |
Sundar, R Rha, S.Y Yamaue, H Katsuda, M Kono, K Kim, H.S Kim, C Mimura, K Kua, L.-F Yong, W.P |
author_sort |
Sundar, R |
title |
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
title_short |
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
title_full |
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
title_fullStr |
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
title_full_unstemmed |
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer |
title_sort |
phase i/ib study of otsgc-a24 combined peptide vaccine in advanced gastric cancer |
publishDate |
2020 |
url |
https://scholarbank.nus.edu.sg/handle/10635/175397 |
_version_ |
1800914361681707008 |